PMID- 18670452
OWN - NLM
STAT- MEDLINE
DCOM- 20090310
LR  - 20231120
IS  - 1476-5500 (Electronic)
IS  - 0929-1903 (Linking)
VI  - 16
IP  - 2
DP  - 2009 Feb
TI  - TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by 
      parvoviral vectors act in synergy to induce antitumor effects in mouse 
      glioblastoma.
PG  - 149-60
LID - 10.1038/cgt.2008.62 [doi]
AB  - Interferon-gamma-inducible protein 10 is a potent chemoattractant for natural 
      killer cells and activated T lymphocytes. It also displays angiostatic properties 
      and some antitumor activity. Tumor necrosis factor-alpha (TNF-alpha) is a 
      powerful immunomodulating cytokine with demonstrated tumoricidal activity in 
      various tumor models and the ability to induce strong immune responses. This 
      prompted us to evaluate the antitumor effects of recombinant parvoviruses 
      designed to deliver IP-10 or TNF-alpha into a glioblastoma. When Gl261 murine 
      glioma cells were infected in vitro with an IP-10- or TNF-alpha-transducing 
      parvoviral vector and were subcutaneously implanted in mice, tumor growth was 
      significantly delayed. Complete tumor regression was observed when the glioma 
      cells were coinfected with both the vectors, demonstrating synergistic antitumor 
      activity. In an established in vivo glioma model, however, repeated simultaneous 
      peritumoral injection of the IP-10- and TNF-alpha-delivering parvoviruses failed 
      to improve the therapeutic effect as compared with the use of a single 
      cytokine-delivering vector. In this tumor model, cytokine-mediated 
      immunostimulation, rather than inhibition of vascularization, is likely 
      responsible for the therapeutic efficacy.
FAU - Enderlin, M
AU  - Enderlin M
AD  - Deutsches Krebsforschungszentrum, Infection and Cancer Program, Heidelberg, 
      Germany.
FAU - Kleinmann, E V
AU  - Kleinmann EV
FAU - Struyf, S
AU  - Struyf S
FAU - Buracchi, C
AU  - Buracchi C
FAU - Vecchi, A
AU  - Vecchi A
FAU - Kinscherf, R
AU  - Kinscherf R
FAU - Kiessling, F
AU  - Kiessling F
FAU - Paschek, S
AU  - Paschek S
FAU - Sozzani, S
AU  - Sozzani S
FAU - Rommelaere, J
AU  - Rommelaere J
FAU - Cornelis, J J
AU  - Cornelis JJ
FAU - Van Damme, J
AU  - Van Damme J
FAU - Dinsart, C
AU  - Dinsart C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080801
PL  - England
TA  - Cancer Gene Ther
JT  - Cancer gene therapy
JID - 9432230
RN  - 0 (CXCL10 protein, human)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Chemokine CXCL10/administration & dosage/immunology/*metabolism/*therapeutic use
MH  - Dendritic Cells/cytology/virology
MH  - Drug Synergism
MH  - Female
MH  - Genetic Vectors
MH  - Glioblastoma/blood supply/*drug therapy/immunology/metabolism/virology
MH  - H-1 parvovirus/physiology
MH  - Humans
MH  - Immunocompetence
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Minute Virus of Mice/physiology
MH  - Necrosis/metabolism
MH  - Tumor Cells, Cultured/cytology/drug effects
MH  - Tumor Necrosis Factor-alpha/administration & 
      dosage/genetics/*metabolism/*therapeutic use
EDAT- 2008/08/02 09:00
MHDA- 2009/03/11 09:00
CRDT- 2008/08/02 09:00
PHST- 2008/08/02 09:00 [pubmed]
PHST- 2009/03/11 09:00 [medline]
PHST- 2008/08/02 09:00 [entrez]
AID - cgt200862 [pii]
AID - 10.1038/cgt.2008.62 [doi]
PST - ppublish
SO  - Cancer Gene Ther. 2009 Feb;16(2):149-60. doi: 10.1038/cgt.2008.62. Epub 2008 Aug 
      1.